Incyte (INCY) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs
May 4, 2017 7:08 AM EDT$251 million of 2017 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 37 percent growth over the same period last year Expanded ECHO program for epacadostat to include multiple pivotal trials in patients with melanoma, non-small cell lung, head & neck, bladder, and renal cancers in combination with PD-1 inhibitors Olumiant® (baricitinib) approved by the European Commission for the treatment of moderate to severe active rheumatoid arthritis; Complete Response Letter (CRL) for baricitinib issued by the FDA
Conference Call and Webcast Scheduled Today at 10:00... More
